<DOC>
	<DOCNO>NCT01058044</DOCNO>
	<brief_summary>The purpose study describe adherence 3 oral anticancer treatment : ) chemotherapeutic regimen capecitabine ( alone association lapatinib ) , ii ) sunitinib tyrosine kinase inhibitor , iii ) non-steroidal aromatase inhibitor . Moreover , study aim evaluate feasibility use `` Medication Event Monitoring System `` ( MEMSÂ® ) order assess adherence oral anticancer treatment deliver dispensary pharmacy .</brief_summary>
	<brief_title>Adherence Oral Anticancer Treatment Using Electronic Monitoring System</brief_title>
	<detailed_description />
	<criteria>Age &gt; 18 year histologically proven malignant tumor document decision treatment ) chemotherapeutic regimen capecitabine ( alone association lapatinib ) , ii ) sunitinib tyrosine kinase inhibitor , iii ) nonsteroidal aromatase inhibitor ambulatory treat subject Subject accept use MEMS monitor automatically compile drug dose history Written inform consent severe concomitant wich make undesirable patient participate study would jeopardize adherence trial protocol patient agree participate program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Cancer , Sunitinib , capecitabine , anastrozole , letrozole</keyword>
	<keyword>adherence , anticancer treatment</keyword>
</DOC>